Answers are grounded in this paper and cite their sources.
Systematic review finds reduced-dose direct oral anticoagulants effectively lower recurrence in VTE patients, suggesting a balance with bleeding risks.
Background Venous thromboembolism (VTE) poses a significant clinical burden, ranking as the third primary contributor to cardiovascular-related mortality. While extended anticoagulation reduces recurrence, it raises bleeding risks. Reduced-dose direct oral anticoagulants (DOACs) may offer an optimal balance by preventing VTE recurrence while minimizing hemorrhage. This meta-analysis evaluated the efficacy and safety of reduced-dose DOACs for secondary VTE prevention.
No takes yet. Share an insight, caveat, or question.
Albukhari et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: